3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
13
Unknown
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Sarcoma
5
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Germ Cell and Embryonal
2
Lymphoma, B-Cell
2
Teratoma
1
Seminoma
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Perivascular Epithelioid Cell Neoplasms
1
Osteosarcoma
1
Nonseminomatous germ cell tumor
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Neoplasms
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Liposarcoma
1
Leukemia, Biphenotypic, Acute
1
Leiomyosarcoma
1
Ichthyosis, X-Linked
1
Hodgkin Disease
1
Interventions
Rituximab
25
Lenalidomide
20
Cyclophosphamide
18
obinutuzumab
8
Vincristine
8
Doxorubicin
8
Prednisone
7
Bendamustine Hydrochloride
7
tazemetostat
6
ibrutinib
6
Biopsy
6
venetoclax
5
pembrolizumab
5
fludarabine
5
Specimen Handling
5
CT-P10
5
fludarabine phosphate
4
R-CHOP protocol
4
Peripheral Blood Stem Cell Transplantation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Prednisolone
3
Etoposide
3
tocilizumab
2
copanlisib
2
axicabtagene ciloleucel
2
atezolizumab
2
acalabrutinib
2
abexinostat
2
Whole-Body Irradiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Follicular
×
Ifosfamide
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled